Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma.

Area of Science:

• Oncology
• Pharmacology
• Hematology

Background:

• The role of statins in augmenting rituximab-based chemotherapy for lymphoma is not well-established.
• Diffuse large B-cell lymphoma (DLBCL) is a common non-Hodgkin lymphoma requiring effective treatment strategies.

Purpose of the Study:

• To investigate the impact of statin use on the efficacy of R-CHOP chemotherapy in treatment-naïve advanced DLBCL patients.
• To explore the relationship between statin intensity and treatment outcomes, including complete response (CR) and progression-free survival (PFS).

Main Methods:

• Retrospective review of advanced DLBCL patients receiving frontline R-CHOP chemotherapy.
• Analysis of differential statin use at the initiation of treatment.
• Comparison of CR rates and six-year PFS between patients with and without statin use, and across different statin intensities.

Main Results:

• Patients receiving statins concurrently with R-CHOP showed a significantly higher CR rate compared to those on R-CHOP alone.
• Medium or high intensity statin use was associated with significantly higher CR rates.
• Six-year PFS was notably higher in patients using medium or higher intensity statins versus low or no statin use.

Conclusions:

• Statin use, particularly at medium to high intensity, appears to enhance the anti-lymphoma activity of R-CHOP in DLBCL.
• The cholesterol pathway's role in doxorubicin sensitivity is supported by in vitro/in vivo data.
• Targeting cholesterol metabolism with statins like lovastatin may represent a viable therapeutic strategy to improve R-CHOP response in DLBCL.